Strongbridge Biopharma plc (NASDAQ:SBBP) Q4 2018 Earnings Conference Call Transcript

Feb 26, 2019 • 08:30 am ET


Strongbridge Biopharma plc (NASDAQ:SBBP) Q4 2018 Earnings Conference Call Transcript


Loading Event

Loading Transcript


Good morning, ladies and gentlemen, and welcome to the Strongbridge Biopharma Corporate Update and Fourth Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions) As a reminder, this call will be recorded.

I would now like to introduce your host for today's conference, Ms. Lindsay Rocco of Elixir Health Public Relations. You now may begin.

Lindsay Rocco

Thank you and good morning, everyone. We are pleased that you could join us today for Strongbridge Biopharma's fourth quarter and full year 2018 earnings conference call. Joining me from Strongbridge this morning are Matthew Pauls, President and Chief Executive Officer; Dr. Fred Cohen, Chief Medical Officer; and Brian Davis, Chief Financial Officer.

Before we begin, I would like to remind you that during this call, the Company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Reference to these risks and uncertainties are made in today's press release and disclosed in detail in the Company's periodic and current event filings with the US Securities and Exchange Commission.

In addition, this presentation includes non-GAAP financial measures. This presentation is not intended to be a substitute for financial results presented in conformity with generally accepted accounting principles in the US Investors and potential investors are encouraged to review the reconciliation of the pro forma financial measures included in the Company's earnings release. The most directly comparable GAAP information and a reconciliation between the non-GAAP and GAAP figures are included in the Company's fourth quarter 2018 earnings release, which has been furnished on Form 8-K.

I will now turn the call over to Matthew Pauls.

Matthew Pauls

Thank you, Lindsay. Good morning everyone and thanks for joining us. For today's call, I'll begin by providing a brief summary of our fourth quarter and full year 2018 highlights and results. And then we'll turn the call over to Dr. Fred Cohen, our Chief Medical Officer, to discuss the ongoing Phase III clinical development program for RECORLEV. Brian Davis, our Chief Financial Officer, will then provide a financial overview. We will then open up the call for questions.

With that, let me start by saying that Strongbridge had a strong fourth quarter from a clinical, commercial and financial perspective, which is a reflection of our momentum and overall success throughout the past year. As you will hear from the team today, our accomplishments in 2018 demonstrate the value of our rare disease strategy and have positioned us for future growth as we continue to identify, develop and commercialize important treatments for rare diseases. Leveraging the momentum from last year, we entered 2019 with a focus on progressing the development of RECORLEV for the treatment of endogenous Cushing's syndrome.

And getting into our most notable fourth quarter accomplishments, let's start with the Novo Nordisk transactions. In December, we significantly strengthened our balance sheet